1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow RET-altered Colon Cancer: new trials by email Literature Review of RET-altered Colon Cancer trials Research Report on RET-altered Colon Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
Adenocarcinoma (1) · Adenocarcinoma, Papillary (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Medullary (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Diseases (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
Bronchial Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Multiple Endocrine Neoplasia (1) · Neoplasms, Ductal, Lobular, and Medullary (1) · Neoplasms, Multiple Primary (1) · Neoplastic Syndromes, Hereditary (1) · Rectal Diseases (1)
pralsetinib (1)
Belgium (1) · China (1) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1) · United States (1)
PMID 34118197, PMID 34118198, PMID 35715405, PMID 35962206, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 40639400, PMID 41886723
2016 (1)